IBOV 172,457.76 ▲ 0.66% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL5.67▼ 0.02% USD/MXN18.58▲ 0.39% USD/CLP994.16▼ 0.13% USD/COP 3,303 — 0.00% USD/PEN3.41▲ 0.16% USD/ARS1,544▼ 0.02% USD/UYU 40.59 — 0.00% USD/PYG6,196— 0.00% USD/BOB 11.59 — 0.00% USD/DOP 60.59 — 0.00% USD/CRC 442.74 — 0.00% USD/GTQ 7.64 — 0.00% USD/HNL 26.91 — 0.00% USD/NIO 36.62 — 0.00% USD/VES911.74▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.69▲ 2.75% USD/TTD6.75— 0.00% EUR/BRL6.25▼ 0.04% BRENT 95.72 ▼ 0.13% WTI 88.66 ▲ 0.11% IRON ORE 161.91 — — COPPER 6.01 ▼ 1.15% GOLD 3,837 ▼ 1.26% SILVER 47.13 ▼ 3.89% SOY 1,226 ▼ 1.35% CORN 444.25 ▼ 0.28% WHEAT 586.75 ▼ 1.10% COFFEE 279.25 ▼ 0.34% SUGAR 18.40 ▲ 0.99% ORANGE JUICE 136.85 ▼ 2.91% COTTON 78.68 ▲ 0.01% COCOA 5,123 ▲ 1.13% BEEF 224.80 ▲ 2.70% CATTLE 335.35 ▼ 0.10% LITHIUM 58.76 ▼ 1.13% PETR4 45.30 — 0.00% VALE3 63.50 — 0.00% ITUB4 42.27 — 0.00% BBDC4 14.52 — 0.00% ABEV3 15.79 — 0.00% BBAS3 15.10 — 0.00% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 — 0.00% RENT3 30.07 — 0.00% AZZA3 15.91 — 0.00% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 — 0.00% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 — 0.00% RANI3 8.18 — 0.00% CSNA3 3.72 — 0.00% IBOV 172,457.76 ▲ 0.66% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL 5.67 ▼ 0.02% USD/MXN 18.59 ▲ 0.41% USD/CLP 994.16 ▼ 0.13% USD/COP 3,303 — 0.00% USD/PEN 3.41 ▲ 0.15% USD/ARS 1,544 ▼ 0.02% USD/UYU 40.59 — 0.00% USD/PYG 6,196 ▲ 3.06% USD/BOB 11.59 — 0.00% USD/DOP 60.59 — 0.00% USD/CRC 442.74 — 0.00% USD/GTQ 7.64 — 0.00% USD/HNL 26.91 — 0.00% USD/NIO 36.62 — 0.00% USD/VES 911.74 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.69 ▲ 2.75% USD/TTD 6.75 ▲ 2.58% EUR/BRL 6.25 ▼ 0.04% BRENT 95.72 ▼ 0.13% WTI 88.66 ▲ 0.11% IRON ORE 161.91 — — COPPER 6.01 ▼ 1.15% GOLD 3,837 ▼ 1.26% SILVER 47.13 ▼ 3.89% SOY 1,226 ▼ 1.35% CORN 444.25 ▼ 0.28% WHEAT 586.75 ▼ 1.10% COFFEE 279.25 ▼ 0.34% SUGAR 18.40 ▲ 0.99% ORANGE JUICE 136.85 ▼ 2.91% COTTON 78.68 ▲ 0.01% COCOA 5,123 ▲ 1.13% BEEF 224.80 ▲ 2.70% CATTLE 335.35 ▼ 0.10% LITHIUM 58.76 ▼ 1.13% PETR4 45.30 — 0.00% VALE3 63.50 — 0.00% ITUB4 42.27 — 0.00% BBDC4 14.52 — 0.00% ABEV3 15.79 — 0.00% BBAS3 15.10 — 0.00% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 — 0.00% RENT3 30.07 — 0.00% AZZA3 15.91 — 0.00% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 — 0.00% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 — 0.00% RANI3 8.18 — 0.00% CSNA3 3.72 — 0.00%
since 2009
Monday, November 16, 2026

New HIV Prevention Shot Approved in US, But High Price Raises Access Questions

By · · 2 min read

Gilead Sciences has received approval from US health authorities for a new HIV prevention shot called Yeztugo. This medicine only needs to be given twice a year. It aims to help people who find it hard to take daily pills to prevent HIV.

Yeztugo is based on the drug lenacapavir. In large studies, it showed strong results. Over 99.9% of people who got the shot did not get HIV. These studies included thousands of adults and teenagers from different backgrounds.

The shot is for people who weigh at least 35 kilograms. It could make HIV prevention easier for many, especially those who forget or cannot take pills every day. But the price is high. Gilead set the yearly cost at over $28,000 in the United States.

Free daily brief — no card needed
Get every Latest News story in one morning email
We build you a personalized brief around the topics you follow — free for 7 days. Love it? Your first month after that is US$1.

Experts say a generic version could cost as little as $25 per year if made in large amounts. This big price gap has raised concerns about who will be able to afford it. To help low- and middle-income countries, Gilead has made deals with six other companies to make cheaper versions.

New HIV Prevention Shot Approved in US, But High Price Raises Access Questions
New HIV Prevention Shot Approved in US, But High Price Raises Access Questions.
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

These deals cover 120 countries. The company also agreed to supply doses for two million people through partnerships with global health groups. However, it will take time for these cheaper versions to become available, and they still need approval in many places.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Exxon gets Guyana approval for a gas project”

The approval of Yeztugo is a big step forward for HIV prevention. But the real challenge is making sure the people who need it most can get it. The price and speed of distribution will decide how much impact this new shot will have on the global fight against HIV.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.